Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: Results of a multicenter phase II study

Tumori

Volumn 92, Issue 1, 2006, Pages 6-12

  Riccardi, Alberto ^a   Brugnatelli, Silvia ^a   Danova, Marco ^a   Giordano, Monica ^b   Pugliese, Palma ^b   Luchena, Giovanna ^b   Grasso, Donatella ^a   Trotti, Giovanni ^c   Bertè, Raffaella ^d   Pansini, Giovanni ^e   Tinelli, Carmine ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b SANT ANNA HOSPITAL   (Italy)

^c BUSTO ARSIZIO HOSPITAL   (Italy)

^d GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^e Oncologia   (Italy)

Author keywords

Advanced breast cancer; Sequential chemotherapy; Weekly docetaxel and gemcitabine

Indexed keywords

ANTHRACYCLINE; CIPROFLOXACIN; CLODRONIC ACID; DOCETAXEL; EPIRUBICIN; FLUCONAZOLE; GEMCITABINE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; HORMONE; NAVELBINE; NETILMICIN; ONDANSETRON; PAMIDRONIC ACID; PIPERACILLIN;

ACUTE DISEASE; ADULT; AGED; ALOPECIA; ANEMIA; APPENDICITIS; ARTHRALGIA; ARTICLE; BONE LESION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DYSPNEA; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HORMONAL THERAPY; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIMARY HEALTH CARE; SENSORY DYSFUNCTION; SEQUENTIAL ANALYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING; WORLD HEALTH ORGANIZATION;

EID: 33645996712     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200102     Document Type: Article

References (30)

1. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault RL, Buzdar AU, Hortobagyi GN: Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer, 85: 104-111, 1999.
2. Biganzoli L, Piccart MJ: The bigger the better?... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer. Ann Oncol, 8: 1177-1182, 1997.
3. Riccardi A, Tinelli C, Brugnatelli S, Pugliese P, Giardina V, Giordano M, Danova M, Richetti A, Fava S, Rinaldi E, Fregoni V, Trotti G, Poli A: Doubling the epirubicin dosage in the 5-fluorouracil, epirubicin and cyclophosphamide (FEC) regimen for advanced breast cancer: a prospective, randomized, multicentric study on antitumor effect and life quality. Int J Oncol, 16: 769-776, 2000.
4. Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL: Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N Engl J Med, 325: 1342-1348, 1991.
5. Falkson G, Gelman RS, Pandya KJ, Osborne CK, Tormey D, Cummings FJ, Sledge GW, Abeloff MD: Eastern Cooperative Oncology Group randomized trial of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol, 16: 1669-1676, 1998.
6. Alba E, Martin M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernandez-Aramburo A, Sanchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group: Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol, 22: 2587-2593, 2004.
7. Hochster HS, Vogel CL, Burman SL, White R: Activity and safety of vinorelbine combined with doxorubicin or fluorouracil as first-line therapy in advanced breast cancer: a stratified phase II study. Oncologist, 6: 269-277, 2001.
8. Brugnatelli S, Riccardi A, Danova M, Pugliese P, Tinelli C, Luchena G, Bernardo A, Giardina G, Fava S, Montanari G, Pedrotti C, Poli AM: Sequential docetaxel and vinorelbine for patients with advanced breast cancer previously treated with anthracyclines: a phase II study. Oncol Rep, 8: 801-805, 2001.
9. O'Shaughnessy J, Nag S, Calderillo-Ruiz G, Jordaan J, Llombart A, Pluzanska A, Pawlicki M, Reyes JM, Sekhon J, Albain KS: Gemcitabine plus paclitaxel (GT) versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): interim results of a global phase III study. Proc Am Soc Clin Oncol, abstr. 25, 2003.
10. Riccardi A, Pugliese P, Danova M, Brugnatelli S, Grasso D, Giordano M, Bernardo G, Giardina G, Fava S, Montanari G, Pedrotti C, Trotti G, Rinaldi E, Poli MA, Tinelli C: A phase II study of sequential 5-fluorouracil, epirubicin and cyclophosphamide (FEC) and paclitaxel in advanced breast cancer (Protocol PV BC 97/01). Br J Cancer, 85: 141-146, 2001.
11. Winer EP, Morrow M, Osborne CK, Harris JR: Malignant tumors of the breast. In: Cancer, Principles and Practice of Oncology. De Vita VT, Hellman S, Rosenberg SA (Eds), pp. 1651-1716, Lippincott Williams and Wilkins, New York, 2001.
12. Miles D, von Minckwitz G, Seidman AD: Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist, 7 Suppl 6: 13-19, 2002.
13. Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer, 35: 292-298, 1997.
14. Pagani O, Sessa C, Nole F, Crivellari D, Lombardi D, Thurlimann B, Hess D, Borner M, Bauer J, Martinelli G, Graffeo R, Zucchetti M, D'Incalci M, Goldhirsch A: Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol, 11: 985-991, 2000.
15. Mavroudis D, Alexopoulos A, Ziras N, Malamos N, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, Tsavaris N, Potamianou A, Rigatos G, Georgoulias V: Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study. Ann Oncol, 11: 1249-1254, 2000.
16. Viens P, Roche H, Kerbrat P, Fumoleau P, Guastalla JP, Delozier T: Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am J Clin Oncol, 24: 328-335, 2001.
17. Vassilomanolakis M, Koumakis G, Drufakou S, Aperis G, Demiri M, Barbounis V, Missitzis J, Efremidis AP: Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer. Canc Chemother Pharmacol, 51: 179-183, 2003.
18. Pectasides D, Dimopoulos MA, Aravantinos G, Kalophonos HP, Papacostas P, Briasoulis E, Cogas E, Papadimitriou C, Skarlos D, Kosmidis P, Fountzilas G: First line combination chemotherapy with docetaxel and vinorelbine in advanced breast cancer. A phase II study. Anticanc Res, 21: 3575-3580, 2001.
19. Brugnatelli S, Danova M, De Bella MT, Vaglica M, Manuguerra G, Riccardi A, Palmeri S: Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study. Oncology, 62: 33-38, 2002.
20. Palmeri S, Vaglica M, Accurso V, Gebbia V, Vassallo E, Danova M, Vetri G, Farris A, Mangiameli A, Manuguerra G, Filippelli G, Lo Russo V: Weekly Docetaxel (doc) + gemcitabine (gem) as first line therapy for advanced breast cancer (ABC): a mulicenter phase II study. Proc Am Soc Clin Oncol, abstr. 1991, 2002.
21. Burstein HJ, Manola J, Younger J, Parker LM, Bunnel CA, Scheib R, Matulonis UA, Gaber JE, Clarke KD, Shulman LN, Winer EP: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol, 18: 1212-1219, 2000.
22. Grasso D, Palmeri S, Riccardi A, Danova M: L'associazione di gemcitabina e docetaxel nel trattamento del carcinoma mammario metastatico. Tumori, 90 (S5): S15-17, 2004.
23. Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S: Weekly taxanes in metastatic breast cancer. Onc Rep, 9: 1047-1052, 2002.
24. Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC: Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol, 17: 3828-3834, 1999.
25. Pazos C, Mickiewicz E, Di Notto MR, Coppola F, Ventriglia M, Jovtis S, Balbiani L, Lewi D, Rondinon M, Temperley G, Trigo M, Bertoncin AM, Pascual M, Uranga G, Cazap E, Breier S, Grasso S, Estevez R, Triguboff E, Alvarez A, Suarez A: Phase II of doxorubicin/taxol in metastatic breast cancer. Breast Cancer Res Treat, 55: 91-96, 1999.
26. Rischin D, Smith J, Millward M, Lewis C, Boyer M, Richardson G, Toner G, Gurney H, McKendrick J: A phase II trial of paclitaxel and epirubicin in advanced breast cancer. Br J Cancer, 83: 438-442, 2000.
27. Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crino L, Conte PF: Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br J Cancer, 90: 31-35, 2004.
28. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol, 21: 588-592, 2003.
29. Joensuu H, Holli K, Heikkinen M, Suonio E, Aro AR, Hietanen P, Huovinen R: Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol, 16: 3720-3730, 1998.
30. Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest: Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer, 101: 704-712, 2004.